** daily **
** daily heikin**
** monthly **
Description
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101. The Company’s other development candidate under collaboration is Debio 0932 (formerly CUDC-305).
Address
4 Maguire Road
LEXINGTON, MA 02421
United States
LEXINGTON, MA 02421
United States
Key stats and ratios
| Q2 (Jun '13) | 2012 | |
| Net profit margin | -23.94% | -96.73% |
| Operating margin | -13.07% | -109.71% |
| EBITD margin | - | -108.96% |
| Return on average assets | -7.79% | -27.84% |
| Return on average equity | -16.47% | -44.28% |
| Employees | 33 |
No comments:
Post a Comment